As reported on Scientific American, a growing body of research suggests that Alzheimer’s disease progression is driven by a complex interplay between beta-amyloid plaques and tau neurofibrillary tangles. While both…
As reported on PharmaBiz, Roche has secured CE mark approval for its Elecsys Neurofilament Light Chain (NfL) assay, a blood-based test designed to help detect neuroinflammation in adults with relapsing-remitting…
A pivotal study recently published in the journal Gero Science has revealed new insights into how individual brain regions age and why some are more severely disrupted by Alzheimer's disease…
Axsome Therapeutics has reached a significant regulatory milestone with the US Food and Drug Administration's acceptance of a supplemental New Drug Application (NDA) for AXS-05 as a treatment for agitation…
A Wake Forest University School of Medicine study reports that two existing medications (empagliflozin (Jardiance), a diabetes drug, and intranasal insulin) could improve brain health in individuals with mild cognitive…
A new study published in Aging-US reveals that Parkinson’s disease (PD) patients diagnosed in their 80s are significantly more likely to exhibit amyloid-beta buildup, which is an early marker of…
JCR Pharmaceuticals Co., Ltd., a leader in therapies for rare and genetic diseases, has reached an important milestone in its ongoing collaboration with Alexion, AstraZeneca’s rare disease division. The achievement,…
In a recent study, deficiency in Vitamin D was associated with an elevated risk of developing Alzheimer’s disease. Yet there were no indications that it is the direct cause of…
After the death of six patients, the FDA has announced that it will require earlier and more frequent monitoring of the monoclonal antibody Leqembi, the brand name for the Alzheimer’s…
A new study by MIT researchers reveals new potential targets such as cellular pathways and genes that have not been previously linked to Alzheimer’s. These results may provide answers to…
This week, the FDA approved the first blood-based diagnostic test for Alzheimer's disease (AD). The test, known as "Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio," is designed to detect amyloid…
Scientists have earnestly delved into a new study to test a drug for individuals who have genetically inherited a type of early-onset Alzheimer’s disease known as “dominantly inherited Alzheimer’s disease”.…
Athletes experiencing multiple brain injuries now have more to worry about than ever. Excessive traumas to the brain common in sports like boxing and football, are now being linked to…
The Riken Center team, headed by Dr. Takaomi Saido and using mice with Alzheimer’s, discovered that dopamine may lessen the brain’s physical symptoms and improve memory. The study, featured in…
Written by Linda Shows Let me start with, I’m BLESSED even though I have Alzheimer’s disease (AD). I am a blessed wife, mother, daughter, sister, friend, dog mom, nurse and…
In 2023 a 19-year-old male teenager was suffering from memory decline that first began when he was 17 years of age. His cognitive losses continued during the next few years.…
This article was written by and shared with permission from Shannon Wieloch, MS. Shannon is a certified genetic counselor and patient advocate for the Aicardi-Goutiere Syndrome Advocacy Association and founder of Stork Genetics.…
It is estimated that over six million people in the U.S. have Alzheimer’s disease plus millions of other people throughout the world. Alzheimer’s is the most common type of dementia.…
A team of scientists from Japan appear to have pioneered a method for reversing synapse damage in an Alzheimer's disease mouse model. Although encouraging, the theory must be tested in…
The idiom ‘third time’s a charm’ may have some significance in this instance. The panel that advises the FDA just voted unanimously in favor of Eli Lilly’s experimental drug, donanemab.…
BioSpace recently published a press release discussing the interim results highlighting a Coya Therapeutics’ study. The study evaluates the safety, tolerability, and biological activity of LD IL-2 in 38 patients…
During the past three years two drugs (Aduhelm and Leqembi) that were designed to slow the progression of Alzheimer’s disease, have been approved. A verdict by the FDA on a…
Alzheimer’s disease is a progressive neurodegenerative disease and the most common form of dementia. People with Alzheimer’s disease may have difficulty remembering information, problems with learning, sleep disruptions, poor judgment,…
Researchers have demonstrated renewed interest in vaccines that treat Alzheimer’s. The treatments remove toxic proteins from the brain. The author of a recent article in Reuters interviewed ten researchers and…
Editor's Note: Chronic conditions and rare diseases don't discriminate, Patient Worthy and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
